Posts Tagged ‘Dr Dale Bredesen’

Ron Martin (genetics and nutrition) and Babry Orem (radiation-plant based nutraceutical) next guests

Monday, May 20th, 2019

OLYMPUS DIGITAL CAMERA

Ron Martin received his BS and MS degrees in Food Science and Nutrition from Chapman University, in Orange, California.  He worked for more than 35 years in the nutraceutical and food industries, including Hunt-Wesson/ConAgra, Plus Products, the William. T. Thompson Co., and the Nutrilite division of Alticor, where he served as Senior Research Scientist in Nutrilite’s New Concepts group.  Ron has been a Professional member of the Institute of Food Technologists (IFT) and is President of Nutrigenetics Unlimited, Inc., which he founded in 2007 (www.Nutrigenetics.net). He is also one of the founding members of the International Society of Nutrigenetics/Nutrigenomics (ISNN, www.NutritionAndGenetics.org).

 

Founder and CEO of Folium Px, Babry Oren was born in the former Soviet Republic of Georgia in 1949. Since 1982, Mr. Oren has owned and operated BAO Corporation in Beverly Hills, California that manufactures and distributes Folium Px , and also serving as its chief executive officer. From 1982 to 1988, that company dealt primarily in oil and gas land acquisition, exploration, drilling, and domestic development. Since its inception, its operational and financial aspects have been managed by Babry Oren.  From 1988 to today, Mr. Oren has continued to serve BAO Corporation as CEO, participating in the same business of acquiring domestic and international land for gas and oil contracts. The role of that company and its president would soon change, however: in 1991, he was appointed as a representative of commercial affairs for the Republic of Georgia in the western United States. In 2001, Mr. Oren was appointed as the Representative of the Peace Fund of Georgia, a non-profit organization, in the United States. His company also expanded its services to include wireless telecommunications and internet to the Russian Federations. Mr. Oren is the founder of an ongoing  telecommunications and Internet businesses in one of Russia’s largest cities. Mr. Oren graduated from in the former Soviet Union with a Master’s degree in Economics/Specification in Industrial Planning.  Three years later, he completed schooling at the Export Institute of Israel in Tel Aviv. Mr. Oren is fluent in over six languages and has traveled extensively throughout the noted regions. Folium Px, which Mr Orem will speak about is a plant based nutraceutical that was developed in Georgia in the former Soviet Union and has the purpose of cleansing free radicals by inactivating them to improve the health of people previously exposed to radiation.  https://foliumpx.com/our-board-of-directors/

Enjoy the Interview Below:

 

 

 

Alzheimers-Here today. Gone tomorrow. Good News.

Sunday, November 19th, 2017

 

 

 

 

 

 

Dr. Dale Bredesen is internationally recognized as an expert in the mechanisms of neurodegenerative diseases such as Alzheimer’s disease. He graduated from Caltech, then earned his MD from Duke University Medical Center in Durham, NC. He served as Chief Resident in Neurology at the University of California, San Francisco (UCSF) before joining Nobel laureate Stanley Prusiner’s laboratory at UCSF as an NIH Postdoctoral Fellow. He held faculty positions at UCSF, UCLA and the University of California, San Diego. Dr. Bredesen directed the Program on Aging at the Burnham Institute before coming to the Buck Institute in 1998 as its founding President and CEO.  Dr Bredesen has mentored many, many physicians and PhD learners in his lab, presented over 300 papers, written over 200 peer reviewed papers written numerous book chapters and abstracts,, written several books including his recent the End of Alzheimer’s: The first program to prevent and reverse cognitive decline, received numerous patents and honors. In addition, recently he has been interviewed on many television  and radio shows including Dr Oz. You can see his curriculum vitae at: https://docs.wixstatic.com/ugd/1a2e49_f0a51bffa9a341dca2ab7af9b6fd0c3d.pdf

The uniform failure of recent drug trials in Alzheimer’s disease has highlighted the critical need for a more accurate understanding of the fundamental nature of Alzheimer’s disease. Dr. Bredesen’s research has led to new insight that explains the erosion of memory seen in Alzheimer’s disease, and has opened the door to a new therapeutic approach. He has found evidence that Alzheimer’s disease stems from an imbalance in nerve cell signaling: in the normal brain, specific signals foster nerve connections and memory making, while balancing signals support memory breaking, allowing irrelevant information to be forgotten. But in Alzheimer’s disease, the balance of these opposing signals is disturbed, nerve connections are suppressed, and memories are lost. This model is contrary to popular dogma that Alzheimer’s is a disease of toxicity, caused by the accumulation of sticky plaques in the brain. Bredesen believes the amyloid beta peptide, the source of the plaques, has a normal function in the brain — promoting signals that allow some of the nerve connections to lapse. Thus the increase in the peptide that occurs in Alzheimer’s disease shifts the memory-making vs. memory-breaking balance in favor of memory loss. This work has led to the identification of several new therapeutic candidates that are currently in pre-clinical trials.

Dr. Bredesen’s novel insights into the fundamental nature of Alzheimer’s disease recently attracted an investment of $3.5 million toward a $10 million goal for initial clinical trials of these new therapeutics. This generous support came from the private venture capitalist Douglas Rosenberg, who is helping to fund the Alzheimer’s Drug Discovery Network, centered at the Buck Institute. The unit is screening drug candidates to find those that can preserve a healthy balance in the signaling pathways that support memory. Dr. Bredesen’s work on nerve cell signaling is also the focus of a collaboration between the Buck Institute and BioMarin Pharmaceuticals, Inc., which is seeking treatments for a rare form of Alzheimer’s disease, early onset Familial Alzheimer’s Disease (eFAD), which may develop in people as young as 30 years of age.

Listen to the Interview below: